Phathom Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for gastrointestinal diseases. The company develops...
| Metric Name | Value | Trend | |
|---|---|---|---|
| Dividend Yield | 0.0% | ||
| P/E Ratio | -1.0x | ||
| Revenue | 55.252 M | ||
| Net Income to Company | -334.3 M |
| PHAT | Peers | Sector | |
|---|---|---|---|
Market Cap | 333.7 M | 303.9 M | 60.571 M |
Price % of 52 Week High | 24.8% | 45.8% | 59.6% |
Dividend Yield | 0.0% | 0.0% | 0.0% |
Shareholder Yield | -69.6% | -8.6% | -0.7% |
1 Year Price Total Return | -55.8% | -19.4% | -14.8% |
Beta (5 Year) | 0.35 | 0.97 | 0.64 |
| (presentment in millions) | Trailing Twelve Months | Fiscal Quarters | |||
|---|---|---|---|---|---|
| Period Ending | Dec-22 | Dec-23 | Dec-24 | Dec-23 | Dec-24 |
| Income Statement | |||||
| Revenue | 0.68 | 55 | 0.68 | 30 | |
| Operating Income | (172) | (167) | (277) | (70) | (59) |
| Net Profit | (198) | (202) | (334) | (80) | (74) |
| Diluted EPS | -5.05 | -3.93 | -5.29 | -1.39 | -1.05 |
| EBITDA | (172) | (167) | (277) | (70) | (59) |
| Balance Sheet | |||||
| Cash & ST Invest. | 155 | 381 | 297 | 381 | 297 |
| Current Assets | 161 | 397 | 360 | 397 | 360 |
| Total Assets | 165 | 414 | 378 | 414 | 378 |
| Current Liabilities | 26 | 39 | 86 | 39 | 86 |
| Total Liabilities | 240 | 487 | 632 | 487 | 632 |
| Total Equity | (75) | (73) | (254) | (73) | (254) |
| Total Debt | 207 | 446 | 555 | 446 | 555 |
| Cash Flow Statement | |||||
| Cash Flow Operations | (147) | (138) | (267) | (44) | (63) |
| Cash From Investing | (1.04) | (1.63) | (0.14) | (0.47) | (0.01) |
| Cash From Financing | 120 | 368 | 183 | 212 | 26 |
| Free Cash Flow | (148) | (139) | (267) | (44) | (63) |